| Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients (NCT05380414) | Centre Leon Berard | 2022-07-01 |
| Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer (NCT05298020) | The Affiliated Hospital of Xuzhou Medical University | 2022-04-01 |
| Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer (NCT05162118) | Zhejiang University | 2022-03-08 |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer (NCT05100329) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-11-01 |
| ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies (NCT05085548) | ProDa BioTech, LLC | 2021-10-29 |
| IMC001 for Clinical Research on Advanced Digestive System Malignancies (NCT05028933) | Zhejiang University | 2021-09-30 |
| A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer (NCT04928625) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2021-08-06 |
| Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer (NCT04931381) | Changhai Hospital | 2021-06-01 |
| Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer (NCT04803851) | Peking Union Medical College Hospital | 2021-05-12 |
| A Study of Irinotecan Liposome in Advanced Pancreatic Cancer (NCT04796948) | Jiangsu HengRui Medicine Co., Ltd. | 2021-04-08 |
| The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer (NCT05438797) | Sizhen Wang | 2021-04-02 |
| APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma (NCT04643405) | Ascentage Pharma Group Inc. | 2021-03-17 |
| Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy (NCT04707118) | Fudan University | 2021-02-23 |
| Pancreatic Adenocarcinoma Signature Stratification for Treatment (NCT04469556) | University Health Network, Toronto | 2020-10-14 |
| Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer. (NCT04482257) | CSPC Ouyi Pharmaceutical Co., Ltd. | 2020-07-07 |
| Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer (NCT04239001) | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | 2020-02-01 |
| A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer (NCT04228601) | Jiangsu HengRui Medicine Co., Ltd. | 2020-01-21 |
| Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients (NCT04217096) | Fudan University | 2020-01-01 |
| 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma (NCT04098081) | University of Maryland, Baltimore | 2019-12-12 |
| A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies (NCT04104672) | Arcus Biosciences, Inc. | 2019-11-06 |
| A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer (NCT04137536) | Memorial Sloan Kettering Cancer Center | 2019-10-17 |
| Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors (NCT03889795) | Danae Hamouda, MD | 2019-06-05 |
| Web-based Treatment Information Tool for People With Advanced Pancreatic Cancer (NCT03632850) | Bournemouth University | 2019-02-19 |
| Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer (NCT03662035) | Changzhou No.2 People's Hospital | 2018-09-15 |
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer (NCT03509298) | Fuda Cancer Hospital, Guangzhou | 2018-04-12 |
| A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer (NCT03331562) | Translational Genomics Research Institute | 2017-12-27 |
| A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer (NCT03336216) | Bristol-Myers Squibb | 2017-12-18 |
| Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer (NCT03415802) | Aiping Zhou | 2015-05-11 |
| Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer (NCT02101580) | Polaris Group | 2014-11-17 |
| Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer (NCT02135822) | Chinese PLA General Hospital | 2014-05-01 |
| Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer (NCT02124317) | Chinese PLA General Hospital | 2014-04-01 |
| Supportive Care Intervention-Pancreas (NCT01885884) | University of Pittsburgh | 2013-07-01 |
| Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma (NCT01764477) | Prism Pharma Co., Ltd. | 2013-04-01 |
| A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer (NCT01303172) | Immodulon Therapeutics Ltd | 2011-06-01 |
| Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer (NCT01010945) | OSI Pharmaceuticals | 2010-02-03 |
| Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer (NCT01048320) | Royal Marsden NHS Foundation Trust | 2006-07-01 |